Expert Perspectives on JAK Inhibitors in Dermatology Care - Episode 9
Experts in dermatology review how JAK inhibitors will impact dermatology care across the board.
Jerry Bagel, MD, MS: We’re getting toward the end. Other disease states are being studied with JAK inhibitors. Talk about granuloma annulare, sarcoidosis, and lichen planus.
Brett King, MD, PhD: It feels like the sky is the limit. A 5-patient prospective open-label clinical trial using tofacitinib recently showed amazing results with severe granuloma annulare. With sarcoidosis, we can often evaporate skin disease and watch internal organ disease go away. With severe oral lichen planus, we can make it go away. There was a recent publication in JAMA Dermatology—not a prospective clinical trial, but upadacitinib in a real-world setting of patients with hidradenitis suppurativa—in which patients who had not previously achieved success, were achieving success. I really believe that JAK inhibitors are going to continue to wow us and show us that there’s possibility where we thought that there was nothing for patients.
Jerry Bagel, MD, MS: As we embarked 20 years ago on biologic therapy in psoriasis, it was like we needed a cookbook because we didn’t know what to do. We’re learning along the way. I agree that we have to collaborate with other physicians to make some of these tougher decisions.
I want to thank you, Dr King, for coming here for this wonderful, insightful discussion. Thank you to our audience for watching this HCPLive® presentation. We hope you found this Peers & Perspectives® discussion to be useful and informative. Thank you very much.